|
"muro k"的相关文件
显示项目 11-35 / 38 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-01-28T01:06:19Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Van Cutsem E.;Narita Y.;Pentheroudakis G.;Baba E.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Kato K.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Nakajima T.E.;Shitara K.;Kawakami H.;Tsushima T.;Yoshino T.;Lordick F.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Lordick F.;Tsushima T.;Pentheroudakis G.;Baba E.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Kato K.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Nakajima T.E.;Shitara K.;Kawakami H.;Narita Y.;Yoshino T.;Van Cutsem E.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
|
Chao, J.;Fuchs, C.S.;Shitara, K.;Tabernero, J.;Muro, K.;Van, Cutsem E.;Bang, Y.-J.;De, Vita F.;Landers, G.;Yen, C.-J.;Chau, I.;Elme, A.;Lee, J.;Özgüroǧlu, M.;Catenacci, D.;Yoon, H.H.;Chen, E.;Adelberg, D.;Shih, C.-S.;Shah, Shah S.;Bhagia, P.;Wainberg, Z.A. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
|
McRee A.J; Chia-Chi Lin; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang Y.-J.; Bang Y.-J.;Koshiji M;Juco J;Emancipator K;Lunceford J;Pathiraja K;Chia-Chi Lin;McRee A.J;Burtness B;Le D.T;Golan T;Eder J.P;Gupta S;Catenacci D;Geva R;Shankaran V;Chung H.C;Muro K; Muro K; Chung H.C; Shankaran V; Geva R; Catenacci D; Gupta S; Eder J.P; Golan T; Le D.T; Burtness B |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort
|
Seiwert T.Y.; Cheng J.D; Pathiraja K; Dolled-Filhart M; Meister A; Chung H.C; Chow L.Q.M; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder J.P; Burtness B; Lee S.-H; Keam B; Kang H; Muro K; Weiss J; Geva R; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
|
Cheng J; Chow L.Q.M; Haddad R.; Pathiraja K; Aurora-Garg D; Ray A; Chia-Chi Lin; Chung H.C; Geva R; Mehra R; Seiwert T.Y; Gupta S; Weiss J; Gluck I; Eder J.P; Burtness B; Tahara M; Keam B; Kang H; Muro K |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor �] (TGF-�]) and PD-L1
|
Chia-Chi Lin; Doi T; Muro K; Hou M.-M; Esaki T; Hara H; Chung H.-C; Osada M; Helwig C; Kondo S. |
| 國家衛生研究院 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
|
Chen, LT;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, W;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N |
| 國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-05-13 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T;Kang, YK;Chao, Y;Ryu, MH;Kato, K;Cheol Chung, H;Chen, JS;Muro, K;Ki Kang, W;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Tanimoto, M;Chen, LT;Boku, N |
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國家衛生研究院 |
2018-12-01 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
|
Kato, K;Satoh, T;Muro, K;Yoshikawa, T;Tamura, T;Hamamoto, Y;Chin, K;Minashi, K;Tsuda, M;Yamaguchi, K;Machida, N;Esaki, T;Goto, M;Komatsu, Y;Nakajima, TE;Sugimoto, N;Yoshida, K;Oki, E;Nishina, T;Tsuji, A;Fujii, H;Kunieda, K;Saitoh, S;Omuro, Y;Azuma, M;Iwamoto, Y;Taku, K;Fushida, S;Chen, LT;Kang, YK;Boku, N |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Van Cutsem, E;Narita, Y;Pentheroudakis, G;Baba, E;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Kato, K;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Nakajima, TE;Shitara, K;Kawakami, H;Tsushima, T;Yoshino, T;Lordick, F;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Lordick, F;Tsushima, T;Pentheroudakis, G;Baba, E;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Kato, K;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Nakajima, TE;Shitara, K;Kawakami, H;Narita, Y;Yoshino, T;Van Cutsem, E;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
显示项目 11-35 / 38 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
